10-Q: GT Biopharma Reports Q1 2025 Financial Results, Cites Progress in Clinical Trials and Cost Reduction Efforts

GT Biopharma reports a net loss of $776,000 for Q1 2025, highlighting advancements in clinical trials and cost-cutting measures.

Summary

• GT Biopharma, Inc. reported a net loss of $776,000 for the three months ended March 31, 2025, compared to a net loss of $2,266,000 for the same period in 2024.
• The company's research and development expenses increased to $1,099,000 from $777,000 year-over-year, driven by scientific research costs.
• Selling, general, and administrative expenses decreased significantly to $833,000 from $2,314,000, attributed to cost reduction measures.
• The company's cash and cash equivalents totaled $2,365,000 as of March 31, 2025, down from $3,951,000 at the end of 2024.
• GT Biopharma is focused on developing immuno-oncology products based on its TriKE and Dual Targeting TriKE platforms.
• The company initiated study enrollment for GTB-3650, targeting relapsed/refractory AML and high-grade MDS, in January 2025.
• GT Biopharma is advancing GTB-5550, a B7-H3 targeted TriKE, through preclinical studies.
• The company has a stockholders deficit of approximately $1 million as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• GT Biopharma is pursuing additional financing to fund operations and address its liquidity needs.
• The company entered into a common shares purchase agreement for up to $20 million and a securities purchase agreement for $5.45 million subsequent to the quarter's end.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in reducing its net loss and advancing its clinical trials, it faces significant financial challenges, including a stockholders deficit and the need for additional financing. The going concern warning and Nasdaq compliance issues further dampen the sentiment.

Positives

• Net loss decreased significantly year-over-year, indicating improved financial performance.
• Cost reduction measures led to a substantial decrease in selling, general, and administrative expenses.
• The company initiated study enrollment for GTB-3650, marking progress in clinical development.
• A legal services firm reduced the company's prior year unpaid fees by approximately $1 million, improving the financial position.
• Subsequent to the quarter, GT Biopharma entered into agreements for potential capital infusions.

Negatives

• The company has a stockholders deficit of approximately $1 million, raising substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents decreased, indicating a need for additional financing.
• The company is involved in ongoing legal proceedings, which could result in financial liabilities.
• The company has received a notification from Nasdaq regarding non-compliance with the Minimum Stockholders Equity Requirement.

Risks

• The company's ability to continue as a going concern is uncertain due to its stockholders deficit and ongoing losses.
• Failure to secure additional financing could force the company to delay, reduce, or eliminate some or all of its discretionary spending.
• Ongoing legal proceedings could result in financial liabilities.
• The company's non-compliance with Nasdaq's Minimum Stockholders Equity Requirement could lead to delisting.
• The company is dependent on the success of its TriKE and Dual Targeting TriKE platforms, which are still in development.

Future Outlook

The company is focused on advancing its clinical trials and securing additional financing to fund operations and address its liquidity needs. GT Biopharma believes it has stockholders equity on an unaudited proforma basis of at least $ 2.5 million as of the date of the filing of this Form 10-Q.

Management Comments

• The company is focused on developing immuno-oncology products based on its TriKE and Dual Targeting TriKE platforms.
• The company is pursuing additional financing to fund operations and address its liquidity needs.

Industry Context

GT Biopharma operates in the competitive immuno-oncology space, focusing on novel therapies that harness the power of natural killer cells. The company's TriKE and Dual Targeting TriKE platforms represent a unique approach compared to traditional T-cell immunotherapies, potentially offering a safer alternative with fewer side effects.

Comparison to Industry Standards

• GT Biopharma's approach of using TriKEs to engage NK cells differs from companies like Kite Pharma (Gilead) and Novartis, which focus on CAR-T cell therapies.
• Unlike Amgen's BiTE platform, GT Biopharma's TriKEs include IL-15, aiming to enhance NK cell proliferation and persistence.
• The company's focus on B7-H3 as a target aligns with broader industry interest, with companies like MacroGenics also developing B7-H3 targeting therapies.
• GT Biopharma's financial position is weaker than larger, established players in the immuno-oncology field, requiring ongoing fundraising efforts.

Legal Proceedings

• The Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer, for breach of fiduciary duties and breach of contract.
• Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York, alleging that it was assigned TWF's rights under the Notes and seeks enforcement and damages.

Related Party Transactions

• The company has a significant concentration of expenses incurred from and accounts payable to Cytovance, a related party, and the University of Minnesota.
• During the three months ended March 31, 2025, the Company issued pre-funded warrants to purchase up to 326,251 shares of common stock exercisable at $ 0.0001 per share with a fair value of approximately $ 847,000 to Cytovance as partial payment of accounts payable.

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises and the risk of delisting from Nasdaq.
• Employees' job security is uncertain due to the company's financial challenges.
• Customers (patients) may benefit from the development of new therapies, but the company's financial instability could delay or halt progress.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• Continue clinical development of GTB-3650 and GTB-5550.
• Secure additional financing to fund operations.
• Address Nasdaq compliance issues.
• Respond to Z-One, LLC's Summons with Notice in the Supreme Court of the State of New York, County of New York.
• Continue to monitor the Ohri Matter and prepare for the final hearing scheduled for June 10th through June 12th, 2025.

Key Dates

Keywords

GT Biopharma, TriKE, Dual Targeting TriKE, Financial Results, Clinical Trials, GTB-3650, GTB-5550, AML, MDS, Immuno-oncology, Warrants, Preferred Stock, Capital Raise, Going Concern